超声心动图在癌症治疗期间及治疗后临床决策中的当代作用
综述阐述超声心动图是癌症治疗相关心功能障碍(CTRCD)检测与监测的基石,尽管专业学会和监管机构已发布监测、诊断和治疗指南,但因肿瘤人群中无症状左室功能不全预后价值证据不足,其作为标准诊疗的采纳仍有限。美国食品药品监督管理局(FDA)对所有接受曲妥珠单抗乳腺癌患者的心脏监测计划频率是否合适受到质疑,无症状左室功能不全时中断还是继续肿瘤治疗仍是临床难题。整体纵向应变(GLS)正成为有前景的工具,有助于选择和优化心血管结局。
要点
- 超声心动图是癌症治疗期间及治疗后检测和监测CTRCD的基石。
- 专业学会和监管机构已发布CTRCD监测、诊断和治疗指南,但作为标准诊疗的采纳仍有限。
- 整体纵向应变(GLS)正成为告知和促进癌症治疗选择、优化心血管结局的有前景工具。
核心结论
- 尽管存在局限性,超声心动图左室功能测量在临床决策中继续发挥关键作用,整体纵向应变(GLS)正成为告知和促进癌症治疗选择、优化心血管结局的有前景工具。
研究设计与样本
- 综述,检索范围与纳入文献原文未报告。
诊断标准与关键数值
- 专业学会和监管机构已发布关于CTRCD监测、诊断和治疗方法指南,但作为标准诊疗的采纳仍有限,因肿瘤人群中无症状左室功能不全预后价值证据不足。
- FDA推荐的心脏监测计划适用于所有接受曲妥珠单抗治疗的乳腺癌患者,其频率是否合适受到质疑。
临床应用与阅片要点
- 超声心动图左室功能测量在临床决策中继续发挥关键作用。
- 整体纵向应变(GLS)正成为告知和促进癌症治疗选择、优化心血管结局的有前景工具。
- 无症状左室功能不全时中断还是继续肿瘤治疗仍是临床难题,因心脏功能障碍风险与肿瘤疗效获益的平衡不确定。
局限性
- 肿瘤人群中无症状左室功能不全预后价值的证据不足,导致指南作为标准诊疗的采纳仍有限。
- FDA推荐的所有接受曲妥珠单抗乳腺癌患者心脏监测计划频率是否合适受到质疑。
- 无症状左室功能不全时中断还是继续肿瘤治疗仍是临床难题,因心脏功能障碍风险与肿瘤疗效获益的平衡不确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Early recognition of cancer therapy-related cardiac dysfunction (CTRCD) provides an opportunity to mitigate cardiac injury and risk of developing late cardiac events. Echocardiography serves as the cornerstone in the detection and surveillance of CTRCD in patients during and after cancer therapy. Guidelines from professional societies and regulatory agencies have been published on approaches to surveillance, diagnosis, and treatment of CTRCD, although adoption as standard of care remains limited given the lack of evidence on the prognostic value of asymptomatic left ventricular (LV) dysfunction in the oncology population. The frequency of cardiac monitoring and the appropriateness of the Food and Drug Administration (FDA)-recommended cardiac monitoring schedule in all patients receiving trastuzumab for breast cancer has been challenged. Interruption versus continuation of oncological therapy in the setting of asymptomatic LV dysfunction remains a clinical conundrum given the uncertain balance of the risk of cardiac dysfunction and benefit of oncology efficacy. Despite their limitations, echocardiographic measures of LV function continue to play a pivotal role in clinical decision making, with global longitudinal strain emerging as a promising tool in informing and facilitating the selection of cancer treatment and optimizing cardiovascular outcomes. This review highlights the key recommendations of the existing guidelines and discusses recent developments in cardio-oncology imaging practices with the aim of providing practical guidance on the role and use of echocardiography in challenging clinical cases in cardio-oncology.
引用
- Liu J, Banchs J, Mousavi N, et al. Contemporary Role of Echocardiography for Clinical Decision Making in Patients During and After Cancer Therapy. JACC Cardiovasc Imaging. 2018. PMID: 30092969. doi:10.1016/j.jcmg.2018.03.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。